Skip to content

Study With Fascigel

Multi-centre, Open-label, First-in-man Study With Fascigel Used in Adult Patients Suffered From Back Pain

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05625984
Enrollment
55
Registered
2022-11-23
Start date
2022-10-24
Completion date
2023-11-13
Last updated
2024-02-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Back Pain

Brief summary

The product is a Class III Medical Device. Structure is made by 1% sodium hyaluronate polysaccharide in normal saline solution. The device intended use is to help treat back pain by lubricating fascia.

Interventions

DEVICEFascigel

The product is a Class III Medical Device. Structure is made by 1% sodium hyaluronate polysaccharide in normal saline solution.

Sponsors

Contipro Pharma a.s.
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Back pain (VAS above 4 cm) * Limited range of motion * Duration of pain for over 3 months * Patient willing and able to provide the written consent * Ability to communicate well with the investigator in the local language, and to understand and comply with the requirements of the study

Exclusion criteria

* State after back surgery * BMI \> 35 * Age \< 18 years * Pregnant or lactating woman * Patient in terminal stage of living * Patient with known hypersensitivity or allergy to any of substances contained in Medical Device * Patient participating in the intervention clinical study * Alcohol or drug abuse * Patient undergoing chronic coagulation therapy

Design outcomes

Primary

MeasureTime frameDescription
- Pain management3 monthsVisual Analogue Scale - 0-100 - higher scores mean a worse outcome

Countries

Czechia

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026